Skip to main content
Journal cover image

Thrombospondin-based antiangiogenic therapy.

Publication ,  Journal Article
Zhang, X; Lawler, J
Published in: Microvasc Res
2007

Thrombospondins (TSPs) are a family of extracellular matrix proteins that regulate tissue genesis and remodeling. TSP-1 plays a pivotal role in the regulation of both physiological and pathological angiogenesis. The inhibitory effects of TSP-1 on angiogenesis have been established in numerous experimental models. Among other TSP members, TSP-2 has equivalent domain structure as TSP-1 and shares most functions of TSP-1. The mechanisms by which TSP-1 and -2 inhibit angiogenesis can be broadly characterized as direct effects on vascular endothelial cells and indirect effects on the various angiogenic regulators. The fact that TSP-1 and -2 are potent endogenous angiogenic inhibitors has prompted studies to explore their therapeutic applications, and detailed understanding of the mechanisms of action of TSP-1 and -2 has facilitated the design of therapeutic strategies to optimize these activities. The therapeutic effects can be achieved by up-regulation of endogenous TSPs, or by the delivery of recombinant proteins or synthetic peptides that contain sequences from the angiogenic domain of TSP-1. In this article, we review the progress in thrombospondin-based antiangiogenic therapy and discuss the perspectives on the significant challenges that remain.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Microvasc Res

DOI

ISSN

0026-2862

Publication Date

2007

Volume

74

Issue

2-3

Start / End Page

90 / 99

Location

United States

Related Subject Headings

  • Thrombospondins
  • Neovascularization, Pathologic
  • Humans
  • Endothelium, Vascular
  • Endothelial Cells
  • Cardiovascular System & Hematology
  • Animals
  • Angiogenesis Inhibitors
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, X., & Lawler, J. (2007). Thrombospondin-based antiangiogenic therapy. Microvasc Res, 74(2–3), 90–99. https://doi.org/10.1016/j.mvr.2007.04.007
Zhang, Xuefeng, and Jack Lawler. “Thrombospondin-based antiangiogenic therapy.Microvasc Res 74, no. 2–3 (2007): 90–99. https://doi.org/10.1016/j.mvr.2007.04.007.
Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res. 2007;74(2–3):90–9.
Zhang, Xuefeng, and Jack Lawler. “Thrombospondin-based antiangiogenic therapy.Microvasc Res, vol. 74, no. 2–3, 2007, pp. 90–99. Pubmed, doi:10.1016/j.mvr.2007.04.007.
Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res. 2007;74(2–3):90–99.
Journal cover image

Published In

Microvasc Res

DOI

ISSN

0026-2862

Publication Date

2007

Volume

74

Issue

2-3

Start / End Page

90 / 99

Location

United States

Related Subject Headings

  • Thrombospondins
  • Neovascularization, Pathologic
  • Humans
  • Endothelium, Vascular
  • Endothelial Cells
  • Cardiovascular System & Hematology
  • Animals
  • Angiogenesis Inhibitors
  • 3202 Clinical sciences
  • 1103 Clinical Sciences